VTVera Todorovic

Vera Todorovic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vera Todorovic has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Marjan Micev

    Department of Pathohistology, First Surgical University Hospital, Institute for Digestive Diseases, Clinical Center of Serbia, Belgrade, Serbia

    5 shared publications
  • Mileva Mićić

    Institute for Medical Research, University of Belgrade, Belgrade, Serbia

    2 shared publications
  • Mirela Budeč

    Institute for Medical Research, University of Belgrade, Belgrade, Serbia

    2 shared publications
  • Aleksandra Sokic Milutinovic

    1 shared publication
  • Dimitrije Brašanac

    Institute of Pathology, School of Medicine, University of Belgrade, Belgrade, Serbia

    1 shared publication
  • Goran Barisic

    First Surgical Clinic, Clinical Centre of Serbia, Belgrade

    1 shared publication

Latest Publications

  • Insulin-like growth factor-I in wound healing of rat skin

    by Vera Todorović, Predrag Peško, Marjan Micev, Miloš Bjelović, Mirela Budeč, Mileva Mićić, Dimitrije Brašanac, Olivera Ilić-Stojanović


  • G cells and gastrin in chronic alcohol-treated rats

    by Vera Todorović, Vesna Koko, Mirela Budeč, Mileva Mićić, Marjan Micev, Mirjana Pavlović, Sanja Vignjević, Neda Drndarević, Olivera Mitrović


  • Open Access

    Expression of p53 protein in Barrett’s adenocarcinoma and adenocarcinoma of the gastric cardia and antrum

    by Ivan Jovanovic, Vera Todorovic, Tomica Milosavljevic, Marijan Micev, Predrag Pesko, Milos Bjelovic, Yoannis Mouzas, Maria Tzardi

    Background/Aim. Most studies of esophageal and gastric adenocarcinomas have shown a very high rate of p53 gene mutation and/or protein overexpression, but the influence of the tumor site upon the frequency of p53 protein expression has not been evaluated (gastroesophageal junction, Barret's esophagus, and antrum). The aim of our study was to analyze the correlation between the selected clinico-pthological parameters, and p53 protein overexpression in regards to the particular tumor location. Methods. The material comprised 66 surgical specimens; 10 were Barrett?s carcinomas, 25 adenocarcinomas of the gastric cardia (type II adenocarcinoma of the esophagogastric junction - EGJ), and 31 adenocarcinomas of the antrum. Immunostaining for p53 protein was performed on formalin-fixed, paraffin-embedded tissue sections, using the alkaline phosphatase - antialkaline phosphatase (APAAP) method. The cases were considered positive for p53 if at least 5% of the tumor cells expressed this protein by immunostaining. Results. There was no significant difference observed between the studied groups in regards to age, sex, Lauren?s classification and tumor differentiation. There was, however, a significant difference observed in the depth of tumor invasion between Barrrett?s adenocarcinoma and adenocarcinoma of the cardia compared with the adenocarcinoma of the antrum. Namely, at the time of surgery, both Barrett?s adenocarcinomas and adenocarcinomas of the cardia, were significantly more advanced comparing with the adenocarcinomas of the antrum. Overexpression of p53 was found in 40% (4/10) of Barrett?s adenocarcinomas, 72% (18/25) of adenocarcinoma of the cardia and 65% (20/31) of adenocarcinoma of the antrum. No significant differences in p53 expression in relation to sex, type (Lauren) of tumor, depth of invasion, lymph node involvement, or tumor differentiation were observed in any of the analyzed groups of tumors. Patients with more advanced Barrett?s adenocarcinoma and in the cases of lymph node invasion revealed tendency for the greater p53 positivity compared with the early forms and lymph node-negative cases; however, this difference was not significant according to the statistical analysis. With regard to adenocarcinoma of the cardia, higher rates of p53 positivity were recorded in poorly differentiated, more advanced cases with lymph node invasion. Nevertheless, none of these differences was statistically significant. On the contrary, in the patients with adenocarcinoma of the antrum, greater p53 positivity was revealed in early forms without lymph node involvement, but the observed difference was not statistically significant. Conclusion. No significant differences in p53 protein expression in terms of sex, type (Lauren) of tumor, depth of invasion, lymph node involvement, or tumor differentiation were observed in any of the analyzed groups of tumors (Barrett?s adenocarcinoma, adenocarcinoma of the cardia and adenocarcinoma of the antrum).


  • Histopathology of residual rectal carcinoma following preoperative radiochemotherapy

    by Marjan Micev, M. Micev-Cosic, Vera Todorovic, M. Krsmanovic, Zoran Krivokapic, M. Popovic, Goran Barisic, V. Markovic, Ljiljana Radosevic-Jelic, Ivan Popov

    Preoperative radiotherapy with (CRT) or without chemotherapy (RT) in the management of patients with locally advanced rectal carcinoma is increasingly accepted as therapeutic modality to reduce local recurrence and improve survival, decrease tumor size and/or stage, has less toxicity compared to postoperative therapy, improves sphincter preservation and the ability to perform a curative resection. In a brief review of literature we discussed the possible prognostic role of most important pathologic parameters and their clinical implications. At present, predictive value of tumor response to neoadjuvant therapy remains uncertain, whether evaluated as five-point histological tumor regression grade (TRG) or recently proposed three-point rectal cancer regression grade (RCRG). However, most reports emphasize reduced local reccurence rates and disease-free survival advantage in patients with complete tumour regression or tumour down-staging, occuring in up to 20% and 60% of cases, respectively. Patients with advanced post-treatment tumour stage (ypT3/4), positive lymph nodes (ypN1/2), vascular invasion, positive circumferential resection margin, clearance


  • Somatostatin and D cells in patients with gastritis in the course of Helicobacter pylori eradication

    by Aleksandra Sokic Milutinovic, Vera Todorovic, Tomica Milosavljevic, Marjan Micev, Milan Spuran, Neda Drndarevic


  • Open Access

    Two pp-omas of the head of the pancreas one of which with central necrosis fistulated into the duodenum

    by Radoje Colovic, Nikica Grubor, Marjan Micev, Natasa Colovic, Vera Todorovic, Milena Cosic-Micev

    PP omas are rare, usually malignant tumors of the PP cells of the Langerhan?s islets which secrete pancreatic polipeptide. The authors present two women operated for PP-omas of the pancreas. The first was 55 year-old woman in whom we did a cephalic duodenopan-createctomy (Whipple's procedure) for the tumor of the head of the pancreas with central cavity containing gas due to comunication with the duodenum. Imunohistochemistry showed a PP oma with strong generalised immunoreactivity with antibodies against Chromogra-min A, neuron specific enolasa and PP with more the 95% of tumor cells and coexpression of somatostatine in 35% and VIP in less then 5% of tumor cells. Following uneventful recovery the patient stayed symptom free so far and put 20 kilograms in weight. The second patient was 19 year-old girl with a multinodal tumor of almost the entire pancreas in whom a local excision of the nodal mass of the head of the pancreas had been carried out in the other hospital, three years ago and relaparotomy and tumor biopsy a month before admission to our institution. In her we did a total duodenopancreatectomy and standard limphadenectomy for a multinodal mass ocupying almost the entire pancreas. Immunohistochemistry showed a strong generalised immunoreactivity with antibodies agains Chromographin A, Neuron speciphic enolasa and PP for more then 95% of tumor's cells. Glucagon was expressed in few focuses (in less then 1% of cells), somatostatin was expressed very rarely in single cells while the rest of tumor markers did not show a visible immunologic reactions in the majority of tumor's cells. Three years after surgery she died due to multiple liver secondaries.